Sculellaria barbata extraction method and application of total extract of sculellaria barbata in preparation of new coronavirus resisting medicine
Prepared by water extraction or alcohol extraction of the total extract of 3CLpro and PLpro, the problem of resistance to existing drugs by mutant SARS-CoV-2 strains to existing drugs was solved, and a new type of drug was achieved The effective inhibition of coronavirus and the improvement of lung damage have provided new drug ideas for fighting the new coronavirus.
Patent Information
- Application Number
- CN202411258524.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing anti-coronavirus drugs have increased resistance to mutant SARS-CoV-2 virus strains, resulting in a weakening of the effects of vaccines and small-molecular drugs, and lack of effective treatment and preventive measures.
The total extract of samella ceramide is prepared by water extraction or alcohol extraction. It is used as an inhibitor of 3CLpro and PLpro to inhibit the activity of the novel coronavirus replicon virus, and is used to treat and prevent novel coronavirus infection and reduce the viral load in the lungs. and inflammation.
The total extract of the genus Cyperus effectively inhibits the activity of SARS-CoV-2 replicon virus in vitro, improves lung injury in mice, and reduces lung inflammation, providing an effective treatment plan for COVID-19, especially for mutant viruses. Good inhibitory effect.
Smart Images

Figure CN118903250A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of antiviral drugs, and specifically relates to an extraction method of the traditional Chinese medicine Scutellaria barbata and application of its total extract in fighting against the new coronavirus. Background Art
[0002] Novel coronavirus infection (COVID-19), caused by the novel coronavirus (SARS-CoV-2), is a threat to human health. An increasing number of mutant SARS-CoV-2 strains have become resistant to approved drugs, underscoring the urgent need to develop new and effective interventions against SARS-CoV-2 infection.
[0003] Scutellaria barbata is the dried whole herb of Scutellaria barbata D.Don, a plant of the Labiatae family. It is also known as narrow-leaved Han Xin grass and Bingtou grass. Its name was first seen in "Surgery Authentic". It is mainly produced in Hebei, Shandong, southern Shaanxi, Henan, Jiangsu, Zhejiang and other places in China. Scutellaria barbata tastes pungent, bitter, and cold. It enters the lung, liver, and kidney meridians. It clears away heat and detoxifies, removes blood stasis and promotes diuresis. It is often used for carbuncle, sore throat, pain from falls, edema, jaundice, snake and insect bites. Studies have shown that the main components of Scutellaria barbata are chemical components such as terpenes, flavonoids, polysaccharides, and volatile oils, which have multiple pharmacological effects such as anti-tumor, antiviral, antibacterial, antioxidant, and immunomodulatory.
[0004] Scutellaria barbata is one of the heat-clearing and detoxifying drugs, but current research on the pharmacological effects of Scutellaria barbata at home and abroad is mostly focused on the study of anti-tumor mechanisms, while there is less research on the antiviral and anti-inflammatory effects of Scutellaria barbata.
[0005] At present, the global small molecule anti-new coronavirus drugs are mainly concentrated in two major targets: 3-chymotrypsin-like protease (3CL pro ) and RNA-dependent RNA polymerase (RdRp). 3CL pro Also known as 3C-like protease or main protease (Mpro), it is the main protease found in coronaviruses and is an enzyme essential for the replication of the new coronavirus (SARS-CoV-2). proIt is composed of 306 amino acids and is a homodimeric cysteine protease containing three domains (I, II and III). It is involved in most mature cleavages of protein precursors. Since there is no 3CL homologous protein in the human body, the risk of toxic side effects when taking this type of drug is low and the safety is high. Pfizer's Paxlovid, Xianuosin's Ritonavir Tablets, and RAY1216 from Zhongsheng Ruichuang Biotechnology are all 3CLs that act on SARS-CoV-2. pro , inhibiting the cleavage of viral polymeric precursor proteins, thereby blocking viral replication to achieve the effect of anti-SARS-CoV-2.
[0006] Among various RNA virus genes, the only common gene product is RdRp, and because human RNA polymerase does not have RNA polymerase activity that depends on RNA templates, small molecule drugs targeting viral RdRp can avoid interfering with the normal physiological response of host cells. Gilead's Remdesivir, Merck's Molnupiravir, Junshi Bio's VV116, and my country's independently developed Azvudine all inhibit viral replication in the body by interfering with RdRp function.
[0007] VV116 is a novel oral nucleoside antiviral drug. Structurally, VV116 is a derivative of GS-441524 (remdesivir core structure). After optimization and modification of the drug's chemical structure such as deuteration and acylation, the antiviral activity and dosage form advantages have been further enhanced and highlighted. It can more effectively inhibit viral replication and has good oral bioavailability. In this study, we used deuterium remdesivir hydrobromide (VV116) as the positive control of the experiment.
[0008] Papain-like protease (PL pro ) is another cysteine protease encoded by SARS-CoV-2 besides the main protease. PL pro It can cleave nonstructural protein polyprotein precursors (Nsps), which plays a vital role in viral replication. pro It can also inhibit the host immune response by cleaving ubiquitin on host proteins and modifying interferon-stimulated gene 15 (ISG15). pro It is highly conserved among SARS-CoV-2 mutants, making it a highly sought-after antiviral drug target.
[0009] As the virus mutates, vaccines and small molecule drugs are becoming less effective. An increasing number of mutant SARS-CoV-2 strains are becoming resistant to some currently approved drugs. Summary of the invention
[0010] In view of this, the object of the present invention is to provide the use of a total extract of Scutellaria barbata in the preparation of a drug for treating and / or preventing novel coronavirus infection. The total extract of Scutellaria barbata provided in an embodiment of the present invention can effectively inhibit the activity of the novel coronavirus (SARS-CoV-2) replicon virus in vitro and in vivo, and improve the lung injury of mice in vivo, and then have a good therapeutic effect on novel coronavirus (SARS-CoV-2) infection, especially on COVID-19.
[0011] The first aspect of the present invention relates to a method for extracting a total extract of Scutellaria barbata, the extraction method comprising a Scutellaria barbata water extraction method or a Scutellaria barbata alcohol extraction method, wherein the Scutellaria barbata water extraction method comprises:
[0012] Prepare Chinese medicinal materials of Scutellaria barbata, soak them in 10-30 times amount of pure water solution for 30-60 minutes, extract them 1-3 times by decoction method, each time for 1-2 hours, filter and separate the residue, combine the filtrate, and obtain an extract;
[0013] Preferably, the extract is concentrated under reduced pressure to obtain an extract, and more preferably, the extract is freeze-dried to a constant weight to obtain the Scutellaria barbata water extract.
[0014] The Scutellaria barbata alcohol extraction method comprises:
[0015] Prepare Chinese medicinal materials of Scutellaria barbata, soak them in 10-30 times the amount of 70%-95% ethanol solution for 30-60 minutes, reflux extract 1-3 times, each time for 1-2 hours, filter and separate the residue, combine the filtrate, and obtain an extract;
[0016] Preferably, the extract is concentrated under reduced pressure to obtain an extract, and more preferably, the extract is freeze-dried to a constant weight to obtain the Scutellaria barbata ethanol extract.
[0017] The second aspect of the present invention relates to the total extract of Scutellaria barbata as a 3CL pro and PL pro Use of inhibitors;
[0018] Preferably, the Scutellaria barbata total extract is the Scutellaria barbata water extract or the Scutellaria barbata alcohol extract described in the first aspect above.
[0019] The third aspect of the present invention relates to the use of Scutellaria barbata total extract in the preparation of 3CL for inhibiting SARS-CoV-2 pro or PLpro Use in inhibitors of
[0020] Preferably, the Scutellaria barbata total extract is the Scutellaria barbata water extract or the Scutellaria barbata alcohol extract described in the first aspect above.
[0021] The fourth aspect of the present invention relates to the use of the total extract of Scutellaria barbata in resisting SARS-CoV-2 infection;
[0022] Preferably, the Scutellaria barbata total extract is the Scutellaria barbata water extract or the Scutellaria barbata alcohol extract described in the first aspect above.
[0023] The fifth aspect of the present invention relates to the use of the total extract of Scutellaria barbata in the preparation of a drug for reducing the viral load of SARS-CoV-2 virus in the lungs of mammals, improving lung damage and / or reducing lung inflammation;
[0024] Preferably, the Scutellaria barbata total extract is the Scutellaria barbata water extract or the Scutellaria barbata alcohol extract described in the first aspect above;
[0025] Preferably, the mammal is a human or a mouse.
[0026] The sixth aspect of the present invention relates to the use of the total extract of Scutellaria barbata in the preparation of a medicament for treating diseases or conditions related to SARS-CoV-2 infection;
[0027] Preferably, the Scutellaria barbata total extract is the Scutellaria barbata water extract or the Scutellaria barbata alcohol extract described in the first aspect above.
[0028] Beneficial effects of the present invention:
[0029] The total extract of Scutellaria barbata can effectively inhibit the activity of the novel coronavirus (SARS-CoV-2) replicon virus in vitro and in vivo, improve lung injury in mice, and reduce lung inflammation in mice. The present invention provides a new use of the total extract of Scutellaria barbata as a novel coronavirus drug, realizing a new idea for the preparation of drugs to combat the novel coronavirus. The total extract of Scutellaria barbata inhibits the replication of the SARS-CoV-2 replicon virus with high activity, and the IC 50 =1.5mg / mL, CC 50 =9.5mg / mL, SI=6.3; Scutellaria barbata ethanol extract IC 50 =2.4mg / mL, CC 50 =15.7 mg / mL, SI=6.5. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 This is a dose-effect analysis of the total extract of Scutellaria barbata against SARS-CoV-2 replicon virus.
[0031] Figure 2 The total extract of Scutellaria barbata protects body weight in mice infected with SARS-CoV-2 replicon virus. Figure 3 To investigate the effect of Scutellaria barbata aqueous extract on pathological damage in lung tissue of mice infected with SARS-CoV-2 replicon virus.
[0032] Figure 4 To investigate the effects of Scutellaria barbata aqueous extract on lung indices of mice infected with SARS-CoV-2 replicon virus.
[0033] Figure 5 To investigate the effect of Scutellaria barbata aqueous extract on the lung viral load in mice infected with SARS-CoV-2 replicon virus.
[0034] Figure 6 To investigate the effect of Scutellaria barbata aqueous extract on the expression of inflammatory factors in lung tissue of mice infected with SARS-CoV-2 replicon virus.
[0035] Figure 7 Effect of Scutellaria barbata aqueous extract on SARS-CoV-2 3CL pro and PL pro Inhibition of hydrolytic activity. DETAILED DESCRIPTION
[0036] The technical solution of the present invention is described in detail below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.
[0037] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0038] General Experimental Methods
[0039] Cell and virus culture methods
[0040] African green monkey kidney epithelial cells (Vero-E6) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin (10000U / ml). Severe acute respiratory syndrome coronavirus 2 virus replicon particles (SARS-CoV-2 replicon virus) carrying exogenous luciferase gene ΔS-VRP(G)-Luc were prepared in the laboratory and stored in a -80℃ refrigerator.
[0041] Embodiment 1:
[0042] Scutellaria barbata was purchased from Beijing Tongrentang Qilu (Jinan) Pharmacy Co., Ltd., batch number: 20231019.
[0043] Preparation of Scutellaria barbata total extract:
[0044] Scutellaria barbata water extract: prepare Scutellaria barbata Chinese medicinal materials, soak them in 20 times the amount of pure water solution for 30-60 minutes, use decoction method, extract twice, each time for 1 hour, and filter to separate the residue, combine the filtrate to obtain an extract; concentrate the extract under reduced pressure to obtain an extract, and freeze-dry the extract to constant weight; obtain Scutellaria barbata water extract.
[0045] Scutellaria barbata alcohol extract: prepare Scutellaria barbata Chinese medicinal materials, soak them in 20 times the amount of 70% to 95% ethanol solution for 30-60 minutes, reflux extraction twice, each time for 1 hour, and filter out the residue, combine the filtrate to obtain an extract; concentrate the extract under reduced pressure to obtain an extract, and freeze-dry the extract to constant weight; obtain the Scutellaria barbata alcohol extract.
[0046] Embodiment 2:
[0047] Inhibition rate determination: 10 5 Vero-E6 cells were cultured for 12 hours, infected with SARS-CoV-2 replicon virus for 1 hour, and the virus was discarded and washed three times with PBS. The water extract and alcohol extract of Scutellaria barbata were diluted 3 times starting from 50 mg / mL, and added to the complete medium containing the total extract of Scutellaria barbata in gradient dilution. After 24 hours of culture, the Gaussia luciferase activity was measured using the Pierce Gaussia luciferase luminescence detection kit (Thermo Scientific, USA), and the inhibition rate of the total extract of Scutellaria barbata on the virus was calculated.
[0048] Toxicity assay: 10 cells / well were plated in each well of a transparent flat-bottom 96-well plate. 5 Vero-E6 cells. The water extract and alcohol extract of Scutellaria barbata were diluted 3 times starting from 50 mg / mL, and the gradient dilution of complete medium containing Scutellaria barbata total extract was added. After 24 hours of culture, the culture medium was discarded, and PBS was washed once. 10 μL Cell Counting Kit-8 (ThermoScientific, USA) and 90 μL complete culture medium were added to each well. After incubation for 2 hours, the absorbance value of 450 nM was measured. The effect of Scutellaria barbata total extract on the viability of Vero-E6 cells was calculated.
[0049] The results of the dose-effect relationship of Scutellaria barbata total extract are as follows Figure 1 As shown in Figure 2, the total extract of Scutellaria barbata inhibited the replication of replicon viruses in a dose-dependent manner, among which the IC 50 =1.5mg / mL, CC50 =9.5mg / mL, SI=6.3; Scutellaria barbata ethanol extract IC 50 =2.4mg / mL, CC 50 =15.7 mg / mL, SI=6.5.
[0050] Embodiment 3:
[0051] Determination of the effect of Scutellaria barbata on the inhibition of SARS-CoV-2 replicon virus on mouse body weight: Female BLAB / c mice (4-6 weeks old) were selected and housed in a biosafety level 2 laboratory. After 1 day of adaptive feeding with standard feed, the experiment was conducted and randomly divided into 3 groups, 5 in the model group, 5 in the Scutellaria barbata water extract group (4g / kg), and 5 in the Scutellaria barbata alcohol extract group (4g / kg). Two days before nasal drops, the total extract of Scutellaria barbata was administered by gavage twice a day. The SARS-CoV-2 replicon virus was diluted with PBS to contain 3×10 10 The number of copies of the virus. After the mice were anesthetized by isoflurane breathing, 50 μL of virus solution was dripped into the nose to infect the mice, and 25 μL was dripped into each nose. The phosphate buffer was gavaged into the model group, and the other two groups were gavaged twice a day, and the weight changes and survival of the mice were monitored for 5 days.
[0052] The weight change rate of mice Figure 2 The total extract of Scutellaria barbata can protect the weight of mice to a certain extent. In addition, we found that the weight protection effect of Scutellaria barbata water extract is better than that of Scutellaria barbata alcohol extract.
[0053] Embodiment 4:
[0054] Evaluation of the efficacy of Scutellaria barbata against SARS-CoV-2 replicon virus in vivo: Female BLAB / c mice (4-6 weeks old) were selected and housed in a biosafety level 2 laboratory. After 1 day of adaptive feeding with standard feed, the experiment was conducted and divided into 5 groups according to the random number table method, including 3 blank control groups, 6 model groups, 6 VV116 positive drug groups, 6 high-dose Scutellaria barbata water extract groups, and 6 low-dose Scutellaria barbata water extract groups. Two days before nasal drops, oral administration was performed twice a day. The SARS-CoV-2 replicon virus was graded diluted with PBS to contain 2×10 10 The virus with the highest number of copies (copies) was administered with saline to the model group, and the other groups were administered twice a day. After the mice were anesthetized by isoflurane breathing, 50 μL of virus solution was dripped into the nose to infect the mice, with 25 μL dripped into each nose. After 24 hours of infection, the mice were dissected and the lung tissues were removed aseptically.
[0055] Pathological analysis was performed. Figure 3, H&E staining showed that the model group mice had severe pathological damage in the lungs, characterized by interstitial pneumonia, alveolar collapse, diaphragm thickening and mononuclear cell infiltration. The VV116 positive group was able to significantly reduce virus-induced acute lung injury, and the Scutellaria barbata aqueous extract significantly reduced virus-induced acute lung injury in a dose-dependent manner. Similarly, the VV116 positive group and the high-dose 4g / kg Scutellaria barbata aqueous extract group significantly improved the elevated lung index of mice infected with the SARS-CoV-2 replicon virus, such as Figure 4 By comparison, 4g / kg of Scutellaria barbata water extract was as effective as the positive drug VV116 in improving SARS-CoV-2-induced acute lung injury in mice.
[0056] like Figure 5 As shown, the viral genomic RNA level in the lungs of mice was detected by RT-qPCR. The VV116 positive drug group and the higher 4g / kg dose of Scutellaria barbata water extract group significantly reduced the viral load, while the lower 2g / kg dose of Scutellaria barbata water extract group also slightly contributed to the reduction of viral load, but no significance was detected. By comparison, the inhibitory effect of 4g / kg Scutellaria barbata water extract on the viral load of SARS-CoV-2 mice lungs was comparable to that of the positive drug VV116.
[0057] like Figure 6 As shown, the relative expression of inflammatory factors in the lungs of mice was detected by RT-qPCR, and it was found that the expression levels of proinflammatory cytokines (including TNF-α and IL-6) in the lungs of mice in the VV116 positive drug group and the 4g / kg Scutellaria barbata water extract group were correspondingly downregulated. This shows that the Scutellaria barbata water extract can reduce the increase of inflammatory factors in the lungs of mice caused by the virus. By comparison, the inhibitory effect of 4g / kg Scutellaria barbata water extract on the expression of proinflammatory cytokines in the lungs of SARS-CoV-2 mice was comparable to that of the positive drug VV116.
[0058] Embodiment 5:
[0059] Determination of the inhibition rate of enzyme protein activity: The 3CL of SARS-CoV-2 was detected by the water extract of Scutellaria barbata pro and PL pro Activity inhibition experiment.
[0060] 3CL proActivity inhibition experiment: The water extract of Scutellaria barbata was prepared into solutions with mass concentrations of 0.007 mg / mL, 0.021 mg / mL, 0.062 mg / mL, 0.185 mg / mL, 0.556 mg / mL, 1.67 mg / mL, and 5 mg / mL. Take 10 μL of different concentrations of water extract of Scutellaria barbata and 40 μL of protein (final concentration 500 nM) and add them to a 96-well plate and mix well. Incubate at room temperature in the dark for 30 minutes. After quickly adding 50 μL of fluorescent substrate (Dabcyl-KTSAVLQ / SGFRKME-Edans, final concentration 50 μM) to each well, use a multifunctional microplate reader to detect the fluorescence intensity: wavelength 336 / 20nm, 490 / 20nm, interval 30s, vibration plate 3s, continuous 1h, gain value 135. At different concentrations of total extract of Scutellaria barbata, use 3CL pro The V0 curve was drawn with the concentration of 1:1, and the linear regression analysis was performed in GraphPad Prism software to calculate the protease inhibition rate of the extract. 50 It is 0.15mg / mL.
[0061] PL pro Activity inhibition experiment: The water extract of Scutellaria barbata was prepared into solutions with mass concentrations of 0.007 mg / mL, 0.021 mg / mL, 0.062 mg / mL, 0.185 mg / mL, 0.556 mg / mL, 1.67 mg / mL, and 5 mg / mL. Take 10 μL of different concentrations of water extract of Scutellaria barbata and 40 μL of protein (final concentration 100 nM) and add them to a 96-well plate to mix well and incubate at room temperature for 30 minutes. After quickly adding 50 μL of fluorescent substrate (final concentration 30 μM) to each well, use a multifunctional microplate reader to detect the fluorescence intensity: wavelength 360 / 20nm, 460 / 20nm, interval 30s, vibration plate 3s, continuous 1h, gain value 135. At different concentrations of total extract of Scutellaria barbata, use PL pro The V0 curve was drawn with the concentration of 1:1, and the linear regression analysis was performed in GraphPad Prism software to calculate the protease inhibition rate of the extract. 50 It is 0.38mg / mL.
[0062] The present invention uses water extraction or alcohol extraction to obtain the total extract of Scutellaria barbata, and finds that the total extract of Scutellaria barbata has an anti-new coronavirus effect in vivo and in vitro, and can reduce the lung viral load, alleviate lung pathological damage in mice, and reduce the expression of lung inflammatory factors. The extraction method of the present invention is simple and convenient, easy to operate, and easy to implement. In addition, the total extract of Scutellaria barbata can be used as 3CL pro and PL pro effective inhibitor of .
[0063] The applicant declares that the present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
Claims
1. A method for extracting a total extract of Scutellaria barbata, the method comprising a water extraction method of Scutellaria barbata or a ethanol extraction method of Scutellaria barbata, wherein the water extraction method of Scutellaria barbata comprises: Prepare Chinese medicinal materials of Scutellaria barbata, soak them in 10-30 times amount of pure water solution for 30-60 minutes, extract them 1-3 times by decoction method, each time for 1-2 hours, filter and separate the residue, combine the filtrate, and obtain an extract; The Scutellaria barbata alcohol extraction method comprises: Prepare Chinese medicinal materials of Scutellaria barbata, soak them in 10-30 times the amount of 70%-95% ethanol solution for 30-60 minutes, reflux extract 1-3 times, each time for 1-2 hours, filter and separate the residue, combine the filtrate to obtain an extract.
2. The extraction method according to claim 1, wherein After obtaining the extract, the method further comprises the step of reducing the pressure and concentrating the extract to obtain an extract, and preferably freeze-drying the extract to a constant weight to obtain a Scutellaria barbata water extract or a Scutellaria barbata alcohol extract.
3. Scutellaria barbata total extract as 3CL pro or PL pro Use of inhibitors.
4. Preparation of Scutellaria barbata total extract for inhibition of 3CL pro or PL pro Use in inhibitors of.
5. The use according to claim 3 or 4, wherein the 3CL pro and PL pro Derived from SARS-CoV-2.
6. Use of the total extract of Scutellaria barbata in the preparation of a drug for reducing the viral load of SARS-CoV-2 virus in the lungs of mammals, improving lung damage and / or reducing lung inflammation.
7. The use according to claim 6, wherein the mammal is a human or a mouse.
8. Use of the total extract of Scutellaria barbata in the preparation of a medicament for treating diseases or conditions associated with SARS-CoV-2 infection.
9. The use according to any one of claims 3 to 8, wherein the Scutellaria barbata total extract is the extract according to claim 1, or the Scutellaria barbata water extract or the Scutellaria barbata alcohol extract according to claim 2.
Citation Information
Patent Citations
Scutellaria barbata total flavone and its application in preparing influenza virus resisting medicine
CN101167799A
Application of albiflorin in treatment of coronavirus pneumonia
CN115003310A
Application of lactobacillus plantarum CGMCC NO.21720 in preparation of new coronavirus infection resisting medicine
CN118185781A
